Search

everythinglearnresearchcommunity

for

Search:↓

Iontophoresis with a growth factor cocktail helps hair growth in patients with androgenetic alopecia.

Suppressing ODC activity reduces tumor growth in hair follicles.

Targeting CD200 could be a new treatment for rheumatoid arthritis.

Air Vice-Marshal Sir Ralph Jackson significantly advanced dialysis technology in the UK.

The review suggests that while many AKR1C3 inhibitors show promise for treating certain cancers, more research is needed to confirm their effectiveness in humans.

Deferasirox combined with sorafenib reduces liver cancer risk and lessens treatment side effects.

5-α-reductase inhibitors reduce prostate cancer risk but may cause sexual dysfunction and don't affect high-grade tumor or death rates.

The document explains how certain drugs block hormones to treat cancers like breast and prostate cancer.

5-Alpha reductase inhibitors may prevent prostate cancer but are not widely used due to concerns about trial relevance and potential risks, and more research is needed to confirm long-term benefits.

New treatments targeting androgen receptors show promise for drug-resistant prostate cancer.

Finasteride reduces AML cell growth by inhibiting androgen receptors.

JAK inhibitors help treat some diseases but may increase risks of blood clots and cancer in certain patients.

5-Alpha reductase inhibitors are safe long-term but may be outdated for preventing less significant prostate cancer.

Ritlecitinib may cause serious side effects like blood clots in alopecia areata patients.

5 alpha-reductase inhibitors like finasteride may lower prostate cancer risk and improve cancer screening.

Finasteride reduces prostate size, improves urination, and slows prostate cancer progression.

Using 5-α-reductase inhibitors before treatment improves outcomes for patients with metastatic renal cell carcinoma.

5-alpha-reductase inhibitors might help slow down low-risk prostate cancer, but their use should be cautious.

Finasteride reduces prostate cancer risk but may increase high-grade tumors; new drugs and better diagnosis are in development, but funding and industry commitment are challenges.

5α-reductase inhibitors lower overall prostate cancer risk but not high-grade cancer risk; longer-term screening and new treatments show promise.

Blocking DHT production more strongly may help control advanced prostate cancer and improve quality of life.

5α-reductase inhibitors may lower the risk of death from bladder cancer.

5-alpha-reductase inhibitors can lower prostate cancer risk but may increase high-grade tumors and cause sexual side effects.

The drug showed promise in treating renal cell carcinoma with manageable side effects.

Certain drugs that block specific enzymes can help treat prostate diseases.

5α-reductase inhibitors may help with prostate cancer but could increase the risk of severe tumors, so careful use is advised.

Men taking 5-alpha-reductase inhibitors before or after bladder cancer diagnosis had a lower risk of dying from the disease.

Antioxidants can block the cancer-fighting effects of doxorubicin.